PYC Therapeutics Advances PKD Drug with Dose Escalation and Extension Approval
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its Phase 1b trial of PYC-003 for Polycystic Kidney Disease, alongside regulatory clearance for an Open-Label Extension allowing continuous dosing up to 24 months.
- Dose escalation to 2.4 mg/kg approved in Phase 1b trial
- Open-Label Extension permits up to 24 months continuous dosing
- Phase 1a safety data expected in second half 2026
- Phase 1b and extension data anticipated in 2027
- Plans for registrational Phase 2/3 trial pending regulatory alignment
Safety Committee Greenlights Higher Dose in PKD Trial
PYC Therapeutics (ASX:PYC) has taken a significant step forward in its development of PYC-003, a precision medicine candidate targeting Polycystic Kidney Disease (PKD). The Safety Review Committee overseeing the ongoing Phase 1b Multiple Ascending Dose (MAD) study has approved escalation to the higher 2.4 mg/kg dose. This decision follows a thorough review of safety and tolerability data from the earlier Phase 1a Single Ascending Dose (SAD) study and initial dosing results in the Phase 1b trial.
Extension Study Approved to Mirror Registrational Trial Duration
In tandem with the dose escalation, PYC has also received approval from human research ethics and regulatory bodies to commence an Open-Label Extension (OLE) study. This extension will allow patients completing the Phase 1b MAD study to continue receiving PYC-003 for up to 24 months, aligning with the anticipated duration of the registrational combined Phase 2/3 trial planned to follow. Such continuity is crucial for assessing long-term safety and efficacy in a chronic condition like PKD.
Data Milestones and Regulatory Pathway
The company expects to present safety and efficacy data from the Phase 1a SAD study in the second half of 2026. Data from the ongoing Phase 1b MAD study and the OLE are slated for release in 2027, subject to the usual clinical and regulatory uncertainties. Successful completion of these early-phase studies and alignment with regulators will pave the way for the registrational Phase 2/3 trial, designed to support a New Drug Application for PYC-003.
Positioning PYC-003 in the RNA Therapeutics Landscape
PYC Therapeutics is leveraging its proprietary RNA delivery platform to address genetic diseases lacking effective treatments. PYC-003 specifically targets the underlying cause of PKD, a progressive genetic disorder with limited therapeutic options. The company’s strategic focus on monogenic diseases aligns with broader industry trends favouring precision medicine approaches for genetically defined patient populations.
Clinical Development Strategy and Next Steps
The Phase 1b MAD study design includes multiple ascending dose cohorts, with potential for a third cohort depending on emerging dose-response and safety data. Notably, PYC has also secured SRC approval to escalate dosing up to 4 mg/kg in the Phase 1a SAD study if warranted by Phase 1b outcomes. These flexible dosing strategies underscore a cautious yet progressive approach to defining the optimal therapeutic window.
Investors will be watching how the forthcoming data releases in 2026 and 2027 influence the company’s clinical timeline and regulatory interactions. Meanwhile, PYC’s broader RNA pipeline continues to advance, reflecting its commitment to addressing unmet needs in genetic diseases.
Bottom Line?
PYC’s dose escalation and extension approvals mark critical progress in its PKD program, but upcoming clinical data will be pivotal in shaping its regulatory and commercial trajectory.
Questions in the middle?
- Will the higher 2.4 mg/kg dose maintain a favourable safety profile in larger patient cohorts?
- How will data from the Open-Label Extension influence dosing strategies for the registrational trial?
- What regulatory feedback will shape the design and timing of the planned Phase 2/3 trial?
